A phase Ib trial to evaluate the efficacy and safety of buparlisib plus letrozole in patients with metastatic breast cancer

Trial Profile

A phase Ib trial to evaluate the efficacy and safety of buparlisib plus letrozole in patients with metastatic breast cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Feb 2016

At a glance

  • Drugs Buparlisib (Primary) ; Letrozole (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SU2C
  • Most Recent Events

    • 11 Feb 2016 New trial record
    • 12 Dec 2015 Results (n=33) presented at the 38th Annual San Antonio Breast Cancer Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top